Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for February 2008
February 1, 2008
- Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
- Biovail Receives Letter Related to 2003 Cardizem LA Launch Activities from U.S. Attorney's Office
- Vyteris Announces Redirection of Business Towards the Advancement of Peptide Delivery
- Roche Plans to Complete Ventana Offer on February 7th
- Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS)
- Teva Provides Update on Generic Protonix
- Patheon Completes Sale of Niagara-Burlington Commercial Manufacturing Business
- FDA MedWatch- Chantix (varenicline)-Associated With Reports Of Changes In Behavior, Agitation, Depressed Mood, Suicidal Ideation, and Attempted/Completed Suicide
February 4, 2008
- FDA Issues Public Health Advisory on Chantix
- Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
- Progen Expands Drug Development Pipeline Through Acquisition of CellGate
- Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
- Akela Pharma Receives Letter from the FDA Regarding its Pre-clinical Toxicology Studies for Fentanyl Taifun
- GE Healthcare to Acquire Whatman Plc: Recommended Acquisition at 270p Per Share in Cash
- President's FY 2009 Budget Advances Food and Medical Product Safety, and the Safety of FDA-Regulated Imports
- FDA MedWatch- FDA MedWatch- Medtronic Inc. SnychroMed EL Implantable Infusion Pump - Class I Recall
February 5, 2008
- Vertical Search Engine Launches for the Pharmaceutical Industry
- Watson to Distribute Alendronate Tablets
- Senate Finance Chairman Baucus Comments on President’s FY2009 Budget
- EMD Serono Canada Inc.-Raptiva: First Biologic Treatment for Psoriasis to Receive Public Reimbursement in Two Atlantic Provinces
- GSK Extends GeneGo License and Adds New Products
- Affymax Affirms Progress with Takeda Collaboration
February 6, 2008
- Canon Communications Acquires Pharmapack and Enters $9 Billion European Market for Pharmaceutical Packaging
- Neurogen Restructures to Focus Resources on Advancing Clinical Programs
- Biogen Idec Reports Full Year and Fourth Quarter 2007 Results
- Alpharma Announces the Sale of Its Active Pharmaceutical Ingredients Business to 3i for $395 Million in Cash
- Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive Merger Agreement
- Patients Appear to Be at Increased Risk of Adverse Events Within 3 Months After Stopping Clopidogrel Therapy for Acute Coronary Syndrome
- New Schizophrenia Treatment Now Available in Canada
- Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
- Methylgene Exercises Right to Opt-out of HDAC Neurodegenerative Collaboration with EnVivo
- Neurogen Restructures to Focus Resources on Advancing Clinical Programs
- Statement from the American Diabetes Association Related to ACCORD Trial Announcement
- For Safety, NHLBI Changes Intensive Blood Sugar Treatment Strategy in Clinical Trial of Diabetes and Cardiovascular Disease
- FDA Takes Action to Stop the Marketing of Unapproved Injectable Drugs Containing Colchicine
February 7, 2008
- Generic Fosamax Approved
- Alcon's Fourth Quarter Sales Rise 20.0 Percent
- FDA Advisory Committee Supports Efficacy and Safety of Zyprexa Long-Acting Injection (LAI) for Schizophrenia Treatment
- PPD to Acquire InnoPharm Ltd.
- Sen. Grassley Letter to Pharmaceutical Drug Maker About Notice of Drug Trial Findings
- GSK: Preliminary Results Announcement for the year ended 31st December 2007
- Publicis Groupe Acquires La Vie est Belle
- Merck Resolves Federal and State Investigations Related to Certain Past Pricing And Certain Past Sales and Marketing Activities
- Merck to Pay More than $650 Million to Resolve Claims of Fraudulent Price Reporting and Kickbacks
February 8, 2008
- Roche Purchases Shares in Tender Offer for Ventana
- Neurogen Announces R&D Update
- FDA Notifies Public of Adverse Reactions Linked to Botox Use
- FDA issues an Early Communication about an Ongoing Safety Review for Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B)
February 11, 2008
- Commenting on the U.S. Food and Drug Administration (FDA) Early Communication, Allergan Clarifies FDA's Inquiry Relates Primarily to High Dose Medical Uses of Botox, Rather Than Botox Cosmetic for Aesthetic Use
- Bayer HealthCare Affiliate Medrad and Possis Medical Sign Definitive Merger Agreement
- CytRx Receives FDA Correspondence Regarding Phase IIb Arimoclomol Clinical Trial in ALS
- Convera and Canon Communications Launch PharmaLiveSearch.com
- ICON Announces The Acquisition Of Healthcare Discoveries Inc
- Baxter's Multiple-Dose Vial Heparin Linked to Severe Allergic Reactions
February 12, 2008
- Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
- Cell Signaling Technology Announces Continued Collaboration with AstraZeneca to Provide CST's PhosphoScan Platform for Kinase Inhibitor Proteomic Profiling
- Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
- Dana-Farber, Merck &Co. Inc. Enter Agreement to Create 'Team'' Approach to Cancer Drug Development
- Boston Scientific Announces Court Decision
- Teva Reports Fourth Quarter and Full Year 2007 Results
- Dyax Corp. Enters Into Antibody Agreements with Sanofi-aventis for the Fully Human Monoclonal Antibody DX-2240 and Phage Display Technology
- Intertek Acquires BioClin Laboratory in Ireland
- American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
- Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
- Sanofi-Aventis: 2007 Fourth-Quarter and Full-Year Net Sales
- DAS Division of Omnicom Acquires Direct Marketing Shop Kern and Aligns With Rapp Collins Worldwide
- Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
- PriCara Recalls 25 mcg/hr Duragesic (fentanyl transdermal system) CII Pain Patches
February 13, 2008
- Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
- More Americans Are Using More Prescription Drugs
- Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
- DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
- Reps. Dingell, Stupak Request Additional Information on Enhance Trial
- Cellartis Enters Into a Research Collaboration with Pfizer to Develop a Screening System for Detection of Human Toxicity
- Jobson Medical Information LLC Acquires Gerber Communications and Practice Advancement Associates
February 14, 2008
- Cephalon Statement on Federal Trade Commission Action Regarding Provigil Patent Settlements
- West Concludes Agreement with Nektar
- Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis
- Missing Price Information Hampers Usefulness of State Prescription Drug Web Sites
- FTC Sues Cephalon, Inc. for Unlawfully Blocking Sale of Lower-Cost Generic Versions of Branded Drug Until 2012
- AstraZeneca and Nomura Phase4 Ventures Announce Creation of New Company “Albireo”
- Physicians Expect to Decrease First- and Second- Line Use of Vytorin in Wake of ENHANCE Trial Results, According to Study by GfK Market Measures
- Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
- GSK Launches New Website to Help Employers Lower Costs and Improve the Health of Workers
- TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
- Genedata and Roche Join Forces in Proteomics Process
- Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Caremark
February 15, 2008
- Icagen Announces Closing of Investment by Pfizer
- Risk of Peripheral Neuropathy with Sebivo (telbivudine)
- Record Operating Results for Solvay in 2007 of EUR 1.2 billion, up 9% from 2006(+24% in the 4th quarter)
- Announcement in Relation to the Movement in the ClinPhone Share Price
- Vaccinex Antibody Licensed to GlaxoSmithKline
- FDA Proposes Guidance for Dissemination of Information on Unapproved Uses of Medical Products
- KMR Group Assesses Clinical Productivity In Biopharmaceutical Industry
February 19, 2008
- Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
- Roche Completes Tender Offer for Ventana Shares
- EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
- Actavis Recalls Certain Fentanyl Patches in the US as Precaution
- ClinPhone: Statement re: Share Price Movement
- Takeda Discontinues Development of Matuzumab
- Merck Triples 2007 Profit After Tax to EUR 3.5 Billion
- Wyeth Wins Thimerosal-Autism Case in Maryland Court
February 20, 2008
- Oxford Biomedica Announces Data Safety Monitoring Board Recommendation to Continue Trovax Phase III Trist Study
- Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
- pSivida Receives First R&D Payments from Pfizer
- CSL: Interim Result, Strong Profit Growth From Operations, Up 36% to $349 Million
- Pfizer to Acquire Encysive Pharmaceuticals
- Vernalis Announces Management Changes
- Genstruct Announces New Collaboration with Pfizer in Drug Safety
February 21, 2008
- Shire: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
- Millipore Corporation Signs License Agreement with Bayer HealthCare AG
- I-many Closes Acquisition of GHX Pharma Solutions Data Validation Assets
- Merck to Seek Appellate Review of Class Certification Decision in Vioxx Proceedings in Saskatchewan
- Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
- Appellate Court in the Netherlands Upholds Basic Lipitor Patent, Prevents Launch of Ranbaxy Product before November 2011
- MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody Therapies
- Entelos, Inc. and PDL Biopharma Enter Silico Research Agreement
- AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
February 22, 2008
- FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
- Reps. Dingell, Stupak Consider Changing Law Over Heparin Failures
- BMJ: Investigation Reveals "Invisible Influence" of Sponsors in Medical Education
February 25, 2008
- BioAlliance Pharma to Pursue Its Strategy for the Targeted Acquisition of Complementary Products Following the Announcement of the of Immtech Pharmaceuticals' Pafuramidine Program
- Eucreas, a single-tablet combination of Galvus and metformin, set for launch in first EU countries as new treatment for type 2 diabetes
- GPC Biotech Announces Corporate Restructuring and Provides Pipeline Update
- Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
- Addex Achieves First Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc.
- Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik
February 26, 2008
- Genentech Receives Notification of Rejection of Cabilly Patent Claims From Reexamination Process
- Reps. Dingell, Stupak Comment on Pfizer Decision to Pull Lipitor Ads Featuring Dr. Jarvik
- GlaxoSmithKline and Theravance Announce Expansion of the Horizon Programme with Start of Large Phase 2B Study of LABA in COPD Patients
- Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
- Who Benefits from Antidepressants? US Health Inequities
- FDA MedWatch - Avandia (rosiglitazone maleate): new Medication Guide issued
- Statement of Robert Jarvik, MD, President and CEO of Jarvik Heart, Inc. Regarding the Lipitor DTC Advertisements
February 27, 2008
- AstraZeneca Provides Update On Recentin Clinical Development Programme
- Sanofi Pasteur MSD Welcomes Sweden's Decision to Recommend and Fund Human Papillomavirus Vaccination for School Girls
- Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
- Receptor Logic Teams with Sanofi Pasteur to Develop T Cell Receptor Mimics (TCRm) for Vaccine Research
- Switching Medications, Adding Psychotherapy May Help Teens Whose Initial Medication for Depression is Ineffective
- Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
- Agents Used for Treatment of Anemia Associated with Increased Risk of Blood Clots, Death in Patients with Cancer
- GlaxoSmithKline Statement: Public Library of Science Medicine Article on Antidepressant Medicines
- Bruker Corporation Announces Closing of the Acquisition of the Bruker BioSpin Group
- FDA MedWatch - Tysabri (natalizumab) - Reports Of Clinically Significant Liver Injury
February 28, 2008
- AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
- Wenning: 2007 Was Bayer’s Most Successful Year to Date
- Merck Retains Interest in AstraZeneca LP Products
- Novartis and Sony Pictures Television International's Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America
- Support for the Physician Payments Sunshine Act, S.2029
- King Pharmaceuticals Reports Year-End and Fourth-Quarter 2007 Financial Results
- Pfizer to Seek to Appeal Lipitor Enantiomer Patent Ruling in the Netherlands, Company Notes That Ruling Has No Commercial Impact
- Mylan Announces Amendment to Bystolic (Nebivolol) Agreement
February 29, 2008
- Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
- Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
- Generic Drugs Slow Rise in Prescription Drug Costs, Saving $5.2 Billion in 2007
- Interpublic Announces Fourth Quarter and Full-Year 2007 Results
- Pharmacyclics Realigns to Focus on Advancing Expanded Pipeline of Promising Product Candidates
- QPS Closes Acquisition of Bio-Kinetic Clinical Applications
- New Study of Targeted Therapies for Breast Cancer Establishes Model for Global Clinical Trials
